Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
Open Access
- 28 January 2008
- journal article
- Published by Springer Nature in Radiation Oncology
- Vol. 3 (1) , 5
Abstract
The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population, several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy.Keywords
This publication has 17 references indexed in Scilit:
- More on Severe Cutaneous Reaction with Radiotherapy and CetuximabNew England Journal of Medicine, 2007
- Severe Cutaneous Reaction during Radiation Therapy with Concurrent CetuximabNew England Journal of Medicine, 2007
- Temporal Dependence of the Effect of Radiation on Erlotinib-Induced Skin RashJournal of Clinical Oncology, 2007
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006
- Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy FieldJournal of Clinical Oncology, 2006
- The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapiesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell CancerJournal of Clinical Oncology, 2004
- Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBritish Journal of Dermatology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004